Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The person must be willing and able to sign a consent form agreeing to take part in the trial.
- The person must be 18 years of age or older.
- The person must have a confirmed diagnosis of non-small cell lung cancer (NSCLC) through a tissue or cell sample taken by needle, with the cancer at stage II or III as confirmed by scans (such as CT or PET-CT), and must not have received any cancer treatment before.
- The person must have a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity).
- The person must be expected to live for at least 12 weeks.
- The person must have at least one area of cancer that can be measured on scans, according to standard measurement guidelines.
- The person must have adequately functioning major organs, including the liver, kidneys, and blood system.
- The person must have lung function that is strong enough to tolerate surgery.
- The cancer must not have spread to other parts of the body.
- Women who are able to become pregnant must agree to use effective contraception throughout the study and for at least 120 days after completing chemotherapy or the last dose of the study drug (whichever comes later), and must have a negative pregnancy test within 7 days before joining.
- Men who have not been surgically sterilised must agree to use effective contraception throughout the study and for at least 120 days after completing chemotherapy or the last dose of the study drug (whichever comes later).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People diagnosed with lung adenocarcinoma that has confirmed EGFR mutations or ALK rearrangements (specific genetic changes in the cancer).
- People whose tissue samples show any small cell lung cancer components.
- People who have had another type of cancer within the past five years.
- People who have already received any treatment for NSCLC, including surgery, radiation therapy, chemotherapy, targeted therapy, or any experimental treatment.
- People who have certain serious ongoing health conditions, including active infections, poorly controlled high blood pressure, unstable chest pain (angina), chest pain that began within the last 3 months, moderate to severe heart failure, a heart attack within the past 6 months, serious irregular heart rhythms requiring medication, or significant liver, kidney, or metabolic diseases.
- People with an active or suspected autoimmune disease, or a nerve or muscle condition related to cancer that requires treatment affecting the whole body.
- People who are allergic to the trial drug.
- People currently diagnosed with interstitial lung disease (a condition causing scarring or inflammation in the lungs).
- People with HIV infection or active hepatitis.
- Women who are pregnant or breastfeeding.
- People with neurological or psychiatric conditions that would prevent them from cooperating with the trial.
- People who are currently taking part in another treatment-based clinical trial.
- People considered unsuitable for the trial for any other reason, as determined by the trial doctor.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peng Zhang, PhD, Shanghai Pulmonary Hospital, Shanghai, China
Phone: 02165115006
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pathologic complete response (PCR) rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.